Schizophrenia & Psychosis
Search All News
Boosting thalamic activity could help treat cognitive symptoms in schizophrenia related to altered prefrontal cortex function
Source:The New York Times
Chacku Mathai, a project director with OnTrackNY, thinks about whether, if the perfect antipsychotic existed, he would take it. “My experience is so rich,” he said, “I wouldn’t trade it for anything.”
Dr. Aaron Slan, a fourth-year psychiatry resident at Columbia University describes a patients who was acting like someone who had a schizophrenia spectrum illness, but turned out to have COVID-19.
New insights into genetic architecture of disease hold promise for improved risk prediction and novel drug design.
- May 26, 2021
Columbia study also finds people with schizophrenia, overall, have a 4.5-fold increased risk of dying from suicide.
Source:MedscapeMarch 2, 2021
If approved, KarXT— a novel combination of xanomeline with trospium — will be a "landmark" drug, noted Dr. Jeffrey A. Lieberman.
Source:Medpage TodayFebruary 24, 2021
Dr. Jeffrey Lieberman and co-authors hypothesized that combining the xanomeline with trospium could lessen xanomeline's typical side effects in treating schizophrenia.
- February 23, 2021
The Horga Lab is a psychiatry research lab that uses neuroimaging and cognitive methods to study the origins of the psychotic symptoms of schizophrenia, including hallucinations and delusions.
- February 18, 2021
Columbia researchers have published their first report on mass shootings from the Columbia Mass Murder Database (CMMD).
Source:SalonFebruary 5, 2021
A new study reveals that people with schizophrenia are roughly two-and-a-half times more likely to die if diagnosed with COVID-19 than individuals who do not have that mental illness.
Source:Psychiatric TimesDecember 11, 2020
“Our findings open the door for the development of treatments to target specific symptoms of psychosis depending on an individual subject’s symptom profile," says Guillermo Horga, MD, PhD
Source:Psychiatric TimesDecember 2, 2020
Dr. Joshua Kantrowitz discusses a recent trial of CVN058, a drug that may reduce cognitive impairments in individuals with schizophrenia.
- November 9, 2020
Columbia researchers have found a potential neurobiological mechanism for hallucinations and delusions that fits within the hierarchical model of psychosis and can explain their clinical presentation
Source:MedscapeJuly 1, 2020
Dr. Ragy Girgis speaks about the benefits of treating those with psychosis early in their illness.